A Th1-type cytokine named prolactin. facts and hypotheses

Advances in Neuroimmune Biology

Volumn 4, Issue 1, 2013, Pages 1-6

  Parra, Adalberto ^a   Ramírez Peredo, Jorge ^a   Reyes Muñoz, Enrique ^a   Ruiz Argüelles, Alejandro ^b   Ruiz Argüelles, Guillermo J ^b,c  

^a INSTITUTO NACIONAL DE PERINATOLOGÍA   (Mexico)

^b Laboratorios Clinicos de Puebla   (Mexico)

^c CENTRO DE HEMATOLOGÍA Y MEDICINA INTERNA DE PUEBLA   (Mexico)

Author keywords

chronic hepatitis C; graft versus host disease; HIV infection; preeclampsia; Prolactin; Th1 type cytokine

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 2; METOCLOPRAMIDE; PROLACTIN; PROTIRELIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; AMNION FLUID; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC GRAFT VERSUS HOST DISEASE; DISEASE SEVERITY; DOPAMINE METABOLISM; DOWN REGULATION; HEPATITIS C; HORMONE RELEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; HYPERPROLACTINEMIA; IMMUNOREGULATION; LYMPHOCYTE COUNT; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOID CELL; NATURAL KILLER CELL; PATHOGENESIS; PLEIOTROPY; PREECLAMPSIA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROTEIN DEGRADATION; STELLATE CELL; TH1 CELL; TH2 CELL; VIRUS LOAD;

EID: 84880192360     PISSN: 1878948X     EISSN: 18789498     Source Type: Journal    
DOI: 10.3233/NIB-130050     Document Type: Article

References (62)

1. Stricker P, Grueter R. Action du lobe anterieur de l'hypophyse sur la mont́ee laiteuse. CR Soc Biol. 1928; 99: 1978-1980.
2. Riddle O, Bates RW, Dykshom SW. The preparation, identification and assay of prolactin-a hormone of the anterior pituitary. Am J Physiol. 1933; 105: 191-216.
3. Huang P, Guyda H, Friesen HG. Purification of human prolactin. J Biol Chem. 1972; 247: 1955-1957.
4. Guyda H, Huang P, Friesen HG. Immunological evidence for monkey and human prolactin. J Clin Endocrinol Metab. 1971; 32: 120-123.
5. Freeman ME, Kanyieska B, Lerant A, Nagy G. Prolactin: Structure, function and regulation of secretion. Physiol Rev. 2000; 80: 1523-1531.
6. Ben-Jonathan N. Dopamine: A prolactin-inhibiting hormone. Endocr Rev. 1985; 6: 564-569.
7. Iranmanesh A, Mulligan T, Veldhuis JD. Mechanisms subserving the physiological nocturnal relative hypoprolactinemia of healthy older men: Dual decline in prolactin secretory burst mass and basal release with preservation of pulse duration, frequency, and interpulse interval-a General Clinical Research Center study. J Clin Endocrinol Metab. 1999; 84: 1083-1090.
8. Veldhuis JD, Johnson ML. Operating characteristics of the human male hypothalamo-pituitary gonadal axis. Circadian, ultradian and pulsatile release of prolactin, and its temporal coupling with luteinnizing hormone. J Clin Endocrinol Metab. 1988; 69: 116-122.
9. Ben-Jonathan N, Mershan JL, Allen DL, Steinmet RN. Extrapituitary prolactin: Distribution, regulation, function and clinical aspects. Endocr Rev. 1996; 17: 639-669.
10. Matera L. Endocrine, paracrine and autocrine actions of prolactin in immune cells. Life Science. 1996; 59: 599-614.
11. Bern HA, Nicoll CA. The comparative endocrinology of prolactin. Rec Prog Horm Res. 1968; 24: 681-720.
12. Nagy E, Berczi I. Hypophysectomized rats depend on residual prolactin for survival. Endocrinology. 1991; 128: 2776-2784.
13. Nagy E, Berczi I. Immunodeficiency in hypophysectimized rats. Acta Endocrinologica. 1978; 89: 530-537.
14. Nagy E, Berczi I, Friesen HG. Regulation of immunity in rats by lactogenic and growth hormones. Acta Endocrinol. 1983; 102: 351-357.
15. Nagy E, Berczi I. Pituitary dependence of bone marrow function. Br J Hematol. 1989; 71: 457-462.
16. Matera L. Action of pituitary and lymphocyte prolactin. Neuroimmunomodulation. 1997; 4: 171-180.
17. Matera L, Mori M. Cooperation of pituitary hormone prolactin with interleukin-2 and interleukin-12 on production of interferon-gamma by natural killer and T cells. AnnNYAcad Sci. 2000; 917: 505-513.
18. Richards SM, Murphy WJ. Use of human prolactin as a therapeutic protein to potentiate immunohematopoietic function. J Neuroimmunol. 2000; 109: 56-62.
19. Welniak LA, Richards SM, Murphy WJ. Effects of prolactin on hematopoiesis. Lupus. 2001; 10: 700-705.
20. Sun R, Gault RA,Welniak LA, Tian ZG, Richards S, Murphy WJ. Immunologic and hematopoietic effects of recombinant human prolactin after syngeneic bone marrow transplantation in mice. Biol Blood Marrow Transplant. 2003; 9: 426-434.
21. Sun R, Zhang J, Zhang C, Zhang J, Liang S, Sun A, et al. Human prolactin improves engraftment and reconstitution of human peripheral blood lymphocytes in SCID mice. Cell Mol Immunol. 2004; 1: 129-136.
22. Chuang E, Molitch ME. Prolactin and autoimmune diseases in humans. Acta Biomed 2007; 78Suppl. 1: 255-261
23. Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Endocrine Rev. 1996; 17: 518-532.
24. Ĺopez-Karpovitch X, Larrea F, Ćardenas R, Valencia X, Piedras J,D́?az-ŚanchezV. et al. Cellular and humoral immune parameters in women with pathological hyperprolactinemia before and during treatment with bromocriptine.Am .J Reprod Immunol. 1994; 31: 32-39.
25. Bergquist J, Tarkowski A, Ewing A. Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc Nat Acad Sci USA. 1994; 91: 12912-12916.
26. Parra A, Raḿ?rez-Peredo J, Coutiño B, Lagunes B, Maŕ?n A, Ponce de Leon S, et al. Impaired metoclopramide-induced pituitary prolactin release in men with human immunodeficiency virus infection. J Lab Clin Med. 1999; 133: 70-74.
27. Parra A, Raḿrez-Peredo J. The uncoupled couple? Prolactin and CD4 lymphocytes in HIV infection. Med Hypotheses. 1999; 53: 425-428.
28. Parra A, Raḿ?rez-Peredo J, Larrea F, Cabrera V, Coutiño B, Torres I, et al. Decreased dopaminergic tone and increased basal bioactive prolactin in men with human immunodeficiency virus infection. Clin Endocrinol Oxf. 2001; 54: 731-738.
29. Clevenger CV, Freier DO, Kline JB. Prolactin receptor signal transduction in cells of the immune system. J Endocrinol. 1998; 157: 187-197.
30. Gala RR. The physiology and mechanisms of stress-induced changes in prolactin secretion in the rat. Life Sci. 1990; 46: 1407-1420.
31. Kant GJ, Bauman RA, Anderson SM, Mongey EH. Effects of controllable and uncontrollable chronic stress on stress responsive plasma hormones. Physiol Behav. 1992; 51: 1285-1288.
32. Weimann E, Baixeras E, Zamzani M,Kelly P. Prolactin blocks glucocorticoid-induced cell death by inhibiting the disruption of the mitocondrial membrane. Leuk Res. 1999; 23: 751-762.
33. Leff MA, Buckley DJ, Krumenacker JS, Reed JC, Miyashita T, Buckley AR. Rapid modulation of the apoptosis regulatory genes, bcl-2 and bax by prolactin in rat Nb2 lymphoma cells. Endocrinology 1996; 137: 5456-5462.
34. Krumenacker JS, Buckley DJ, Leff MA, McCormack JT, de Jong G, Gout PW, et al. Prolactin-regulated apoptosis of Nb2 lymphoma cells: Pim-1, bcl-2, and bax expression. Endocrine. 1998; 9: 163-170.
35. Parra A, Raḿ?rez-Peredo J, Larrea F, Ṕerez-Romano B, Cabrera V, Torres I, et al. Serum prolactin is associated with apoptosis in men with human immunodeficiency virus infection. Immunol Cell Biol. 2001; 79: 285-290.
36. Clevenger CV, Rusell DA, Appasamy PM, Pristowsky MB. Regulation of interleukin-2-driven T-lymphocyte proliferation by prolactin. Proc Natl Acad Sci USA. 1990; 87: 6460-6464.
37. Clevenger CV, Sillman AL, Hanley-Hyde J, Pristowsky MB. Requirement for prolactin during cycle regulated gene expres sion in cloned T-lymphocytes. Endocrinology 1992; 130: 3216-3222.
38. Veldhuis JD, Iranmanesh A, Johnson ML, Lizarralde G. Twentyfour hour rhythms in plasma concentrations of adenohypophyseal hormones are generated by distinct amplitude and/or frequency modulation of underlying pituitary secretory bursts. J Clin Endocrinol Metab. 1990; 71: 1616-1623.
39. Iranmanesh A, Mulligan T, Veldhuis JD. Mechanisms subserving the physiological nocturnal relative hypoprolactinemia of healthy older men: Dual decline in prolactin secretory burst mass and basal release with preservation of pulse duration, frequency, and interpulse interval-a General Clinical Research Center study. J Clin Endocrinol Metab. 1999; 84: 1083-1090.
40. Parra A, Reyes-Teŕan G, Raḿ?rez-Peredo J, Jacquemin B, Quiroz V, Ćardenas M, et al. Differences in nocturnal basal and rhythmic prolactin secretion in untreated compared to treated HIV-infected men are associated with CD4+ Tlymphocytes. Immunol Cell Biol. 2004; 82: 24-31.
41. Lunn RA, Sumar N, Bansal AS, Treleaven J. Cytokine profiles in stem cell transplantation: Possible use as a predictor of graftversus-host disease. Hematology. 2005; 10: 107-114.
42. Reddy P. Pathophysiology of acute graft-versus-host disease. Hematol Oncol. 2003; 21: 149-161.
43. Hinterberger-Fischer M, Kier P, Spona J, Sebesta C, Tiefengraber E, Habertheuer KH, et al. Prolactin: A possible mediator of graft-versus-host disease following allogeneic bone marrowtransplantation in humans. Bone MarrowTransplant. 1994; 14: 403-406.
44. Hinterberger-Fischer M, Ogris E, Kier P, Bauer K, Kittl E, Habertheuer KH, et al. Elevation of plasma prolactin in patients undergoing autologous blood stem-cell transplantation for breast cancer: Is its modulation a step toward posttransplant immunotherapy? Am J Clin Oncol. 2000; 23: 325-329.
45. Parra A, Raḿrez-Peredo J, Hidalgo R, Morales-Toquero A, Veĺasquez-Raḿrez G, Ruiz-Arg̈uelles A, et al. Altered functional status of the hypothalamic dopaminergic tone in patients with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: A pilot study. Biol Blood Marrow Transplant. 2006; 12: 566-572.
46. Parra A, Raḿrez-Peredo J, Reyes E, Hidalgo R, Maćas- Gallardo J, Lutz-Presno J, et al. Moderate hyperprolactinemia is associated with survival in patients with acute graftversus-host disease after allogeneic stem cell transplantation. Hematology. 2012; 17: 85-92.
47. Mariotti J, Foley J, Ryan K, Buxhoeveden N, KapoorV, Amarnath S, et al. Graft rejection as a Th1-type process amenable to regulation by donor Th2-type cells through an interleukin-4/STAT6 pathway. Blood. 2008; 112: 4765-4775.
48. Herńandez-Ruiz J, Farf́an B, Ćordoba J, Parra A, Raḿ?rez J, Kershenobich D, et al. Effect of prolactin in vitro and in vivo in perforin and TRAIL expression in human NK lymphocyes. Eur J Immunol. 2009; 39Suppl 1: s345-s346.
49. Herńandez-Ruiz J, Herńandez-Medel NL, Parra A, Raḿ?rez-Peredo J, Ramos M, Salgado-Galicia N, et al. NK-cell activation in patients with chronic hepatitis C by mild hyperprolactinemia. Ann Hepatol. 2011; 10: 392-393.
50. Gutíerrez-Reyes G, Ćordova J, Farf́an-Labonne BE, Herńandez-Ruiz J, Parra A, Raḿ?rez-Peredo J, et al. The possible role of prolactin on innate immune response in chronic hepatitis-C. Hepatology 2008; 48Suppl: 1011A.
51. Horrobin DF. The possible role of prolactin in pre-eclampsia. Zentralbl Gynakol. 1977; 99: 526-536.
52. Parra A, Raḿ?rez-Peredo J. The possible role of prolactin in preeclampsia:Ahypothesis revisited a quarter of century later. Med Hypotheses. 2002; 59: 378-384.
53. Lam C, Lim KH, Karumanchi SA. Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia. Hypertension. 2005; 46: 1077-1085.
54. Clapp C, Aranda J, Gonźalez C, Jeziorski MC, Mart́nezdela Escalera G. Vasoinhibins: Endogenous regulators of angiogenesis and vascular function. Trends Endocrinol Metab. 2006; 17: 301-307.
55. Gonźalez C, Parra A, Raḿrez-Peredo J, Garća C, Rivera JC, Macotela Y, et al. Elevated vasoinhibins may contribute to endothelial cell dysfunction and low birth weight in preeclampsia. Lab Invest. 2007; 87: 1009-1017.
56. Berczi I, Katafuchi T. Feto-maternal interactionsundisputable evidence for the concept of neuroimmune biology. Adv neuroim Biol. 2011; 2: 1-4.
57. Orlander H, Peter S, Jarvis M, Ricketts-Hall L. Imipramine induced elevation of prolactin levels in patients with HIV/AIDS improved their immune status. West Indian Med J. 2009; 58: 207-213.
58. Arnold E, Rivera JC, Thebault S, Moreno-Ṕaramo D, Quiroz-Mercado H, Quintanar-St́ephano A, et al. High levels of serum prolactin protect against diabetic retinopathy by increasing ocular vasoinhibins. Diabetes. 2010; 5912: 3192-3197.
59. Triebel J, Macotela Y, de la Escalera GM, Clapp C. Prolactin and vasoinhibins: Endogenous players in diabetic retinopathy. IUBMB Life. 2011; 6310: 806-810.
60. Hilfiker-Kleiner D, Kaminski K, Podewski E, BondaT, Schaefer A, Sliwa K, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell. 2007; 128: 589-600.
61. Yamac H, Bultmann I, Sliwa K, Hilfiker-Kleiner D. Prolactin: A new therapeutic target in peripartum cardiomyopathy. Heart. 2010; 96: 1352-1357.
62. Ignacak A, Kasztelnik M, SliwaT,Korbut RA, Rajda K, Guzik TJ. Prolactin-Not Only Lactotrophin. A "New" View of the "Old" Hormone. J Physiol Pharmacol. 2012; 63: 435-443.